Results 11 to 20 of about 16,360 (195)

Risk of Hepatitis B Virus Reactivation Following Treatment With Abatacept: A Retrospective Study of International Pharmacovigilance Databases

open access: yesEClinicalMedicine, 2022
Summary: Background: Abatacept is a selective T-cell costimulation modulator approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis.
Xiaozhen Geng
exaly   +3 more sources

Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis. [PDF]

open access: yesPLoS ONE, 2020
ObjectivesAbatacept acts as a competitive inhibitor of the CD28/(CD80/86) costimulation signal required for T cell activation. Mechanisms of action of abatacept have not been fully investigated. The objective of this study was to provide detailed insight
Céline Derambure   +4 more
doaj   +2 more sources

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis

open access: yesTherapeutics and Clinical Risk Management, 2014
Chadi Rakieh, Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UKAbstract: Biologic therapies in rheumatoid arthritis are now part of standard ...
Rakieh C, Conaghan PG
doaj   +1 more source

Abatacept as maintenance therapy in kidney transplantation: a retrospective comparative study [PDF]

open access: yesTransplant International
Belatacept use is increasinging in kidney transplantation, as it has demonstrated improved graft survival compared with calcineurin inhibitors. However, its intravenous administration and recurrent supply shortages may limit its use.
Charlotte Uro-Coste   +15 more
doaj   +2 more sources

Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy [PDF]

open access: yesDrug Design, Development and Therapy, 2011
Ofra Goldzweig1, Philip J Hashkes2,31Rainbow Babies and Children's Hospital, Cleveland, OH, USA; 2Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Jerusalem, Israel; 3Cleveland Clinic Lerner Medical School of Case Western Reserve ...
Ofra Goldzweig, Philip J Hashkes
doaj   +2 more sources

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis

open access: yesRheumatology and Therapy, 2023
Introduction One target of rheumatoid arthritis (RA) treatment is to achieve early sustained remission; over the long term, patients in sustained remission have less structural joint damage and physical disability.
Paul Emery   +14 more
doaj   +1 more source

Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data

open access: yesArthritis Research & Therapy, 2021
Background To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials.
Teresa A. Simon   +2 more
doaj   +1 more source

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

open access: yesArthritis Research & Therapy, 2023
Background AVERT-2 (a phase IIIb, two-stage study) evaluated abatacept + methotrexate versus methotrexate alone, in methotrexate-naive, anti-citrullinated protein antibody-positive patients with early (≤ 6 months), active RA.
Paul Emery   +12 more
doaj   +1 more source

Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis

open access: yesArthritis Research & Therapy, 2022
Background Abatacept is a recombinant fusion protein composed of the extracellular domain of cytotoxic T-lymphocyte antigen 4 and the Fc portion of immunoglobulin (Ig) G. The mechanism of action of abatacept in rheumatoid arthritis (RA) is believed to be
Ryosuke Fukue   +3 more
doaj   +1 more source

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain [PDF]

open access: yesFarmacia Hospitalaria, 2014
Objective: To compare the cost of treating rheumatoid arthritis patients that have failed an initial treatment with methotrexate, with subcutaneous aba - tacept versus other first-line biologic disease-modifying antirheumatic drugs. Method: Subcutaneous
R. Ariza   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy